Anne Kasus-Jacobi to Molecular Targeted Therapy
This is a "connection" page, showing publications Anne Kasus-Jacobi has written about Molecular Targeted Therapy.
Connection Strength
0.102
-
Novel neuroendocrine and metabolic mechanism provides the patented platform for important rejuvenation therapies: targeted therapy of telomere attrition and lifestyle changes of telomerase activity with the timing of neuron-specific imidazole-containing dipeptide-dominant pharmaconutrition provision. Recent Pat Endocr Metab Immune Drug Discov. 2014; 8(3):153-79.
Score: 0.102